ClinicalTrials.gov
public full text
Public Domain
CD160 Expression in Corneal Vessels
Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cornea Donor Study#1140006
- Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty#860663
- Platelet Rich Plasma in Corneal Surface Diseases#810318
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection#1101062
- A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty#862976
Record · ID 894122
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive